'Mdr' presentation slideshows

??????? / ?? ????

787 views • 54 slides

Drug Resistant Tuberculosis (DR-TB): An Update

Drug Resistant Tuberculosis (DR-TB): An Update. Dr. Dick Menzies Montreal Chest Institute. Definitions. Primary DR: Resistance in person treated <1 month or not at all Acquired DR: Resistance in person treated > 1 month Mono-drug resistance: Resistance to 1 drug

967 views • 49 slides

MDR and XDR TB

MDR and XDR TB. Bruce A. Bush, M.D. Regional Tuberculosis Consultant Pennsylvania Department of Health Senior Vice President for Medical Affairs Indiana Regional Medical Center. Disclosures. I do not have any financial arrangements or affiliations with a commercial entity. Objectives.

697 views • 38 slides

MANET Extension of OSPF Using CDS Flooding draft-ogier-manet-ospf-extension-05.txt

537 views • 38 slides

Thank you for viewing this presentation.

Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author. 2010 by the author. MDR- and XDR-TB: prevention, treatment and control

454 views • 35 slides

Gram negative infections in hematologic stem cell transplantation

353 views • 35 slides

OSPF-MDR: Extension of OSPF for Mobile Ad Hoc Networks draft-ietf-ospf-manet-mdr-02.txt

OSPF-MDR: Extension of OSPF for Mobile Ad Hoc Networks draft-ietf-ospf-manet-mdr-02.txt. Richard Ogier September 17, 2008. Review of OSPF.

496 views • 32 slides

Gram-Negative Infections in Solid Organ Transplantation

423 views • 28 slides

Thanawat Wongphan 1,2 Pairoj Saonuam 3 . Jongkol Lertiendumrong 1 , Phusit Prakongsai 1

Policy decision on multi drug resistant(MDR) , extreme drug resistant(XDR) tuberculosis screening: How it comes?. Thanawat Wongphan 1,2 Pairoj Saonuam 3 . Jongkol Lertiendumrong 1 , Phusit Prakongsai 1 1 International Health Policy Program(IHPP), Nonthaburi, Thailand

415 views • 22 slides

1.08k views • 21 slides

Issues and lesson learned as a NRL in TB Management (GENETUP)

Issues and lesson learned as a NRL in TB Management (GENETUP). Dr. Bhabana Shrestha NATA/GENETUP 14 th July 2014. German Nepal TB project ( GENETUP). Providing the diagnostic & treatment services since 27 years Pioneer of Directly Observed Treatment Short Course (DOTS)

329 views • 21 slides

Dr. Alexis Niyomwungere National Institute for Public Health Bujumbura, Burundi

The 7th East African Health and Scientific Conference. Use of Electronic devices in Establishing the Risk factors for Multidrug-Resistant Tuberculosis in Bujumbura City, Burundi, 2018. Dr. Alexis Niyomwungere National Institute for Public Health Bujumbura, Burundi. Background.

202 views • 19 slides

Evaluating Potential Drug Therapies

Evaluating Potential Drug Therapies. Mike Shuler Biomedical Engineering. Can we use tissue engineering and related approaches to evaluate potential effectiveness of drugs? Can they be adapted for personalized medicine?. Claudia Fischbach-Teschl Abe Stroock Larry Bonassar Jonathan Butcher.

311 views • 18 slides

WAMHRS

WAMHRS.

392 views • 18 slides

285 views • 17 slides

Treating MDR-TB A Challenge Throughout ECA Public Health Practice II

291 views • 16 slides

Use of OSPF-MDR in Single-Hop Broadcast Networks draft-ogier-ospf-manet-single-hop-00

Use of OSPF-MDR in Single-Hop Broadcast Networks draft-ogier-ospf-manet-single-hop-00. Richard Ogier Presented by Tom Henderson July 28, 2011. Problem Statement and Background.

312 views • 13 slides

Identifying Cases of MDR-TB

Identifying Cases of MDR-TB. Session 3. Old WHO recommendations. New 2010 WHO recommendations.

180 views • 10 slides

CFC COLLABORATION

184 views • 9 slides

Webinar on Risk Management EU MDR Perspective

MakroCare is organizing the webinar on Risk Management EU MDR Perspective. This webinar is designed to focus on the Risk management system should be carefully aligned with and reflected in the clinical evaluation for the device, including the process of clinical risks that needs to be addressed as part of clinical investigations, clinical evaluation and post-market clinical follow up.

45 views • 3 slides